Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
Rallybio (Nasdaq: RLYB), a clinical-stage biotechnology company focused on developing therapies for rare diseases, has announced that its Chief Executive Officer, Stephen Uden, M.D., will deliver a corporate overview at the TD Cowen 45th Annual Health Care Conference.
The presentation is scheduled for Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Rallybio's website at www.rallybio.com.
A replay of the webcast will remain available for 30 days following the presentation, allowing those unable to attend the live event to review the company's updates.
Rallybio (Nasdaq: RLYB), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di terapie per malattie rare, ha annunciato che il suo Amministratore Delegato, Stephen Uden, M.D., presenterà una panoramica aziendale alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
La presentazione è programmata per martedì 4 marzo 2025 alle 1:10 p.m. EST a Boston, MA. Gli investitori e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Eventi e Presentazioni del sito web di Rallybio all'indirizzo www.rallybio.com.
Una registrazione del webcast sarà disponibile per 30 giorni dopo la presentazione, consentendo a coloro che non possono partecipare all'evento dal vivo di rivedere gli aggiornamenti dell'azienda.
Rallybio (Nasdaq: RLYB), una compañía biotecnológica en etapa clínica centrada en el desarrollo de terapias para enfermedades raras, ha anunciado que su Director Ejecutivo, Stephen Uden, M.D., ofrecerá una visión general de la empresa en la 45ª Conferencia Anual de Salud de TD Cowen.
La presentación está programada para el martes 4 de marzo de 2025 a las 1:10 p.m. EST en Boston, MA. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Eventos y Presentaciones del sitio web de Rallybio en www.rallybio.com.
Una repetición del webcast estará disponible durante 30 días después de la presentación, permitiendo a aquellos que no puedan asistir al evento en vivo revisar las actualizaciones de la empresa.
Rallybio (Nasdaq: RLYB)는 희귀 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, CEO인 Stephen Uden, M.D.가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에서 기업 개요를 발표할 것이라고 발표했습니다.
발표는 2025년 3월 4일 화요일 오후 1시 10분 EST에 보스턴, MA에서 예정되어 있습니다. 투자자와 이해관계자는 Rallybio 웹사이트의 이벤트 및 발표 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다: www.rallybio.com.
웹캐스트의 재생은 발표 후 30일 동안 이용 가능하며, 실시간 이벤트에 참석할 수 없는 사람들도 회사의 업데이트를 검토할 수 있습니다.
Rallybio (Nasdaq: RLYB), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de thérapies pour les maladies rares, a annoncé que son Directeur Général, Stephen Uden, M.D., présentera un aperçu de l'entreprise lors de la 45e Conférence Annuelle sur la Santé de TD Cowen.
La présentation est prévue pour le mardi 4 mars 2025 à 13h10 EST à Boston, MA. Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section Événements et Présentations du site web de Rallybio à l'adresse www.rallybio.com.
Une rediffusion du webcast sera disponible pendant 30 jours après la présentation, permettant à ceux qui ne peuvent pas assister à l'événement en direct de revoir les mises à jour de l'entreprise.
Rallybio (Nasdaq: RLYB), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien für seltene Krankheiten konzentriert, hat angekündigt, dass der Geschäftsführer Stephen Uden, M.D. einen Unternehmensüberblick auf der 45. jährlichen Gesundheitskonferenz von TD Cowen präsentieren wird.
Die Präsentation ist für Dienstag, den 4. März 2025 um 13:10 Uhr EST in Boston, MA geplant. Investoren und interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Website von Rallybio unter www.rallybio.com auf einen Live-Webcast der Präsentation zugreifen.
Eine Wiederholung des Webcasts wird für 30 Tage nach der Präsentation verfügbar sein, sodass diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, die Unternehmensupdates überprüfen können.
- Rallybio's participation in a major healthcare conference indicates continued engagement with the investment community
- The company's CEO personally presenting suggests important corporate updates may be shared
- Providing public access to the presentation demonstrates transparency with investors
- The 30-day replay availability shows commitment to information accessibility
- The press release doesn't provide specific details about Rallybio's pipeline or development progress
- No information about the company's financial position is included
- The announcement doesn't mention any new partnerships or collaborations
- There's no indication of upcoming catalysts or significant milestones
A live webcast of the presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcast will be available for 30 days following the presentation.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical needs in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224101688/en/
Investor Contacts
Samantha Tracy
Rallybio Corporation
(475) 47-RALLY (Ext. 282)
investors@rallybio.com
Kevin Lui
Precision AQ
(212) 698-8691
kevin.lui@precisionaq.com
Media Contact
media@rallybio.com
Source: Rallybio Corporation
FAQ
When will Rallybio (RLYB) present at the TD Cowen Health Care Conference?
Who will represent Rallybio (RLYB) at the TD Cowen Conference in 2025?
How can investors access Rallybio's (RLYB) presentation at the TD Cowen Conference?
How long will the replay of Rallybio's (RLYB) TD Cowen Conference presentation be available?